European equities traded in the US as American depositary receipts opened the week lower late Monday morning, declining 0.78% to 1,489.58 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by biopharmaceutical company Cellectis (CLLS) and biotech firm Evaxion (EVAX), which climbed 15.3% and 11.2% respectively. They were followed by accommodations booking company trivago (TRVG) and biopharmaceutical company DBV Technologies (DBVT), which increased 7.4% and 4.4% respectively.
The decliners from continental Europe were led by semiconductor company Sequans Communications (SQNS) and brewing company Anheuser-Busch InBev (BUD), which dropped 25% and 4.8% respectively. They were followed by telecommunications operator Telefonica (TEF) and pharmaceutical company Novo Nordisk (NVO), which lost 2.2% and 2.1% respectively.
From the UK and Ireland, the gainers were led by biopharmaceutical companies Mereo BioPharma Group (MREO) and oil and gas company BP (BP), which rose 2% and 1.6% respectively. They were followed by biotech firm Autolus Therapeutics (AUTL) and Bicycle Therapeutics (BCYC), which were up 1.2% and 0.8% respectively.
The decliners from the UK and Ireland were led by biopharmaceutical company Adaptimmune Therapeutics (ADAP), which plunged 65%, followed by biopharmaceutical company NuCana (NCNA), which was down 3.5%. They were followed by alcoholic beverage company Diageo (DEO) and biopharmaceutical company Amarin (AMRN), which fell 2.7% and 1.6% respectively.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。